《高盛認股證牛熊證》醫療科技股走勢各異 留意高槓桿京健購24921、里康遠牛65272
醫療科技股今早走勢各異，京東健康(6618)獲券商首次給予買入評級，股價急升逾6%，現報105元，從週初的低位明顯反彈。反觀阿里健康(0241)則持續疲弱，股價今早低見17.62元的今年低位，現仍下跌近4%，報17.84元，是現時跌幅最大的藍籌股。另外，平醫(1833)亦上升0.6%，報90.35元
觀察輪證資金流向，過去5個交易日資金持續流入京東健康認購證，合共流入近400萬元，看好可留意京健購24921，屬價外、高槓桿產品，是市場最高槓桿的認購證之一。
京健購24921，行使價151.38元，2021年11月8日到期，實際槓桿6.3倍，市場最高槓桿的認購證之一
阿里健康股價落後吸引資金留意其牛證，而且開始轉倉至收回價較遠的產品，遠牛可留意里康牛65272，是低街貨的選擇；高槓桿、貼價牛則可留意里康牛66960，適合作短線部署。
里康牛65272，收回價16元，行使價15.4元，換股比率50，槓桿比率6.3倍，低街貨遠牛
里康牛66960，收回價17元，行使價16.4元，換股比率50，槓桿比率9.7倍，高槓桿、貼價牛
投資者如看好平醫，認購證可留意平醫購24239，是中期輕微價外證中槓桿最高，是條款及槓桿都突出的產品，值得留意；牛證則可留意貼價牛平醫牛52850，是現時最貼價、最高槓桿的牛證之一。
平醫購24239，行使價99.03元，2021年9月21日到期，實際槓桿7.8倍，行使價90至110元之間、2個月期以上產品中槓桿最高
平醫牛52850，收回價80元，行使價76元，換股比率100，槓桿比率6倍，現時最貼價、最高槓桿的牛證之一
高盛醫療科技股精選：
京健購24921，行使價151.38元，2021年11月8日到期，實際槓桿6.3倍
里康牛65272，收回價16元，行使價15.4元，換股比率50，槓桿比率6.3倍
里康牛66960，收回價17元，行使價16.4元，換股比率50，槓桿比率9.7倍
平醫購24239，行使價99.03元，2021年9月21日到期，實際槓桿7.8倍
平醫牛52850，收回價80元，行使價76元，換股比率100，槓桿比率6倍
註: 以上數據資料來自高盛認股證牛熊證網站https://www.gswarrants.com.hk/~
重要聲明:
以上資訊由第三方提供，AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告，不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料，本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
